Stocks · News reference
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.23) by 126.09 percent. This is a 477.78 percent decrease over losses of $(0.09) per
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
B of A Securities analyst Alec Stranahan maintains Candel Therapeutics (NASDAQ:CADL) with a Neutral and raises the price target from $9 to $12.
Read original at benzingaHC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.
Read original at benzingaFiled: 2026-08-13 AccNo: 0001193125-26-347957 Size: 371 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar